1,3-Benzenediamine, 4-methoxy-, hydrochloride (1:2)

211.08900

210.03300

4MYJ0JWO6G

DTXSID1060637

Crystalline powder

2922299090

61.27000

3.62600

30-32°C

135-140°C 22mm

135-140°C/22mm

Soluble in water

36/37/38

S26-S36/37/39

ST2693000

P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P308+P313, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P405, P501

H302

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

Strong oxidizers.

Evidence is given supporting testing of the class of compounds phenylenediamines for their toxic effects on human health and the environment. The results of toxicity testing of 22 compounds are tabulated as are the effects for which testing is being considered for 13 compounds, and the uses or potential uses of 47 phenylenediamines.[United States EPA; Phenylenediamines; Response to Interagency Testing Committee; Fed Regist 47(5): 973 (1982)]

|Danger|H302 (11.11%): Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P308+P313, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P405, and P501|Aggregated GHS information provided by 9 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Wear appropriate personal protective clothing to prevent skin contact.|Wear appropriate eye protection to prevent eye contact.|Eyewash fountains should be provided in areas where there is any possibility that workers could be exposed to the substance; this is irrespective of the recommendation involving the wearing of eye protection.|Facilities for quickly drenching the body should be provided within the immediate work area for emergency use where there is a possibility of exposure. [Note: It is intended that these facilities provide a sufficient quantity or flow of water to quickly remove the substance from any body areas likely to be exposed. The actual determination of what constitutes an adequate quick drench facility depends on the specific circumstances. In certain instances, a deluge shower should be readily available, whereas in others, the availability of water from a sink or hose could be considered adequate.]|For more Personal Protective Equipment (PPE) (Complete) data for 2,4-DIAMINOANISOLE DIHYDROCHLORIDE (6 total), please visit the HSDB record page.

The worker should immediately wash the skin when it becomes contaminated.|The worker should wash daily at the end of each work shift, and prior to eating, drinking, smoking, etc.|Work clothing that becomes wet or significantly contaminated should be removed and replaced.|Workers whose clothing may have become contaminated should change into uncontaminated clothing before leaving the work premises.

NIOSH considers 2,4-diaminoanisole (and its salts) to be a potential occupational carcinogens.|NIOSH usually recommends that occupational exposures to carcinogens be limited to the lowest feasible concn.|NIOSH considers 2,4-diaminoanisole (and its salts) to be a potential occupational carcinogens. Minimize occupational exposure (especially skin exposures).

Male Wistar rats were divided into two groups. Rats of group 1 were fed basal powdered diet containing 610 ppm 2,4- diaminoanisole sulfate (DAAS), 46 ppm 4,4'-thiodianiline (TDA) and 200 ppm N,N'-diethylthiourea (DETU) for 52 weeks (DTD treatment). Rats of group 2 were maintained on basal diet throughout the experiment as controls. At 52 weeks all surviving rats were sacrificed and subjected to an autopsy. Thyroid, lungs, stomach, liver, spleen, kidneys, testes and all gross lesions suspected of being a tumor were removed. After DTD treatment, the incidence of thyroid hyperplasia and papillary thyroid carcinoma was 59% (10/17) and 65% (11/17), respectively. Hepatocellular adenoma was induced in 2 of 17 rats (12%). Papillary thyroid carcinoma metastasis was found in the lung of 1 rat. No neoplastic tumors were found in kidney, spleen, stomach and testis tissue. /2,4-diaminoanisole sulfate/

The percutaneous absorption of 2,4-diaminoanisole dihydrochloride by hairless rats was approx 2 times higher than that of 2-(2,4-diaminophenoxy)ethanol dihydrochloride because of its high lipid affinity. The penetration of both compounds through the skin was concentration-dependent and studied by (14)C-labelling.

2,4-Diamino(ring-U-14C)anisole 2HCl administered i.p. to rats was excreted chiefly via the urine (79 and 85% of the dose in 24 and 48 h, respectively). The isotope in the feces was 2.1 and 8.9% of the dose at 24 and 48 h. The major metabolic pathway was acetylation of the amine group(s), resulting in 4-acetylamino-2-aminoanisole and 2,4-diacetylaminoanisole. Oxidative pathways yielded 2,4-diacetylaminophenol (O-demethylation), 5-hydroxy-2,4-diacetylaminoanisole (ring hydroxylation) and 2-methoxy-5-(glycolamido)acetanilide or its isomer (omega-oxidation). These major metabolites were excreted in the urine as free and glucuronic acid conjugates.

Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mg/kg up to 200 ml of water for dilution if the patent can swallow, has a strong gag reflex, and does not drool. Administer activated charcoal ... . Cover skin burns with dry sterile dressings after decontamination ... . /Organic bases/Amines and related compounds/|Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag-valve-mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. If patient is unresponsive to these measures, vasopressors may be helpful. Watch for signs of fluid overload ... . Administer 1% solution methylene blue if patient is symptomatic with severe hypoxia, cyanosis, and cardiac compromise not responding to oxygen. ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Organic bases/Amines and related compounds/

/OTHER TOXICITY INFORMATION/ Ingredients found unsafe for use in cosmetics: Ingredient: 4-methoxy-m-phenylenediamine hydrochloride; Safety Concern: carcinogenicity. /From table/

1,3-Benzenediamine, 4-methoxy-, hydrochloride (1:2): ACTIVE